PMID- 27075942
OWN - NLM
STAT- MEDLINE
DCOM- 20170526
LR  - 20220410
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 43
IP  - 6
DP  - 2016 Jun
TI  - Behcet's disease: A comprehensive review with a focus on epidemiology, etiology 
      and clinical features, and management of mucocutaneous lesions.
PG  - 620-32
LID - 10.1111/1346-8138.13381 [doi]
AB  - Behcet's disease (BD) is a chronic, relapsing, inflammatory multisystem disease 
      of unknown etiology. Oral ulcers, genital ulcers, cutaneous lesions, and ocular 
      and articular involvement are the most frequent features of the disease. 
      Mucocutaneous lesions are considered hallmarks of the disease, and often precede 
      other manifestations. Therefore, their recognition may permit earlier diagnosis 
      and treatment with beneficial results for prognosis. BD is particularly prevalent 
      in "Silk Route" populations but has a global distribution. The disease usually 
      starts around the third or fourth decade of life. Sex distribution is roughly 
      equal. The diagnosis is based on clinical criteria, as there is no pathognomonic 
      test. Genetic factors have been investigated extensively, and association with 
      human leukocyte antigen (HLA)-B51 is still known as the strongest genetic 
      susceptibility factor. The T-helper 17 and interleukin (IL)-17 pathways are 
      active, and play an important role, particularly in acute attacks of BD. 
      Neutrophil activity is increased in BD, and the affected organs show a 
      significant neutrophil and lymphocyte infiltration. HLA-B51 association and 
      increased IL-17 response are thought to play a role in neutrophil activation. 
      Treatment is mainly based on the suppression of inflammatory attacks of the 
      disease using immunomodulatory and immunosuppressive agents. Although treatment 
      has become much more effective in recent years with the introduction of newer 
      drugs, BD is still associated with considerable morbidity and increased 
      mortality. Male sex, younger age of onset and increased number of organs involved 
      at the diagnosis are associated with a more severe disease and, therefore, 
      require more aggressive treatment.
CI  - (c) 2016 Japanese Dermatological Association.
FAU - Alpsoy, Erkan
AU  - Alpsoy E
AD  - Department of Dermatology and Venereology, Akdeniz University School of Medicine, 
      Antalya, Turkey.
LA  - eng
SI  - GENBANK/rs116799036
PT  - Journal Article
PT  - Review
DEP - 20160414
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Behcet Syndrome/drug therapy/epidemiology/*etiology/pathology
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Mouth Mucosa/pathology
MH  - Skin/pathology
OTO - NOTNLM
OT  - Behcet's disease
OT  - clinical course
OT  - epidemiology
OT  - etiology
OT  - treatment
EDAT- 2016/04/15 06:00
MHDA- 2017/05/27 06:00
CRDT- 2016/04/15 06:00
PHST- 2015/12/20 00:00 [received]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2017/05/27 06:00 [medline]
AID - 10.1111/1346-8138.13381 [doi]
PST - ppublish
SO  - J Dermatol. 2016 Jun;43(6):620-32. doi: 10.1111/1346-8138.13381. Epub 2016 Apr 
      14.